@article{d73475ef4fc6433c93cbe4c261367b90,
title = "Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report",
abstract = "Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)-mutant advanced-stage non-small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first-generation EGFR-TKI use than with second-generation inhibitors. Herein, we report a case of a patient with advanced-stage EGFR-mutant NSCLC who developed drug reaction with eosinophilia and systemic symptoms (DRESS) after receiving treatment with afatinib. The patient was successfully rechallenged with erlotinib, without manifestations of skin rash in the following 6 months. Hence, erlotinib may be considered a potential substitute for other EGFR-TKIs following DRESS occurrence.",
author = "Lin, {Chung Fu} and Liu, {Szu Yu} and Lo, {Tzu Kun} and Lee, {Julia Yu Yun} and Su, {Po Lan}",
note = "Funding Information: We would like to thank the patient reported here for authorizing the use and disclosure of her health information, and Editage ( www.editage.com.tw ) for English language editing. The present study was funded by grant no. MOST 110‐2314‐B‐006‐102 from the Ministry of Science and Technology, Taiwan. Publisher Copyright: {\textcopyright} 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.",
year = "2022",
month = feb,
doi = "10.1111/1759-7714.14276",
language = "English",
volume = "13",
pages = "494--496",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "3",
}